Cargando…
Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity – initial experience and comparison to [(18)F]FDG PET/CT and MRI
PURPOSE: While [(18)F]-fluorodeoxyglucose ([(18)F]FDG) is the standard for positron emission tomography/computed tomography (PET/CT) imaging of oral squamous cell carcinoma (OSCC), diagnostic specificity is hampered by uptake in inflammatory cells such as neutrophils or macrophages. Recently, molecu...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484183/ https://www.ncbi.nlm.nih.gov/pubmed/34050405 http://dx.doi.org/10.1007/s00259-021-05422-z |
_version_ | 1784577265416273920 |
---|---|
author | Linz, Christian Brands, Roman C. Kertels, Olivia Dierks, Alexander Brumberg, Joachim Gerhard-Hartmann, Elena Hartmann, Stefan Schirbel, Andreas Serfling, Sebastian Zhi, Yingjun Buck, Andreas K. Kübler, Alexander Hohm, Julian Lapa, Constantin Kircher, Malte |
author_facet | Linz, Christian Brands, Roman C. Kertels, Olivia Dierks, Alexander Brumberg, Joachim Gerhard-Hartmann, Elena Hartmann, Stefan Schirbel, Andreas Serfling, Sebastian Zhi, Yingjun Buck, Andreas K. Kübler, Alexander Hohm, Julian Lapa, Constantin Kircher, Malte |
author_sort | Linz, Christian |
collection | PubMed |
description | PURPOSE: While [(18)F]-fluorodeoxyglucose ([(18)F]FDG) is the standard for positron emission tomography/computed tomography (PET/CT) imaging of oral squamous cell carcinoma (OSCC), diagnostic specificity is hampered by uptake in inflammatory cells such as neutrophils or macrophages. Recently, molecular imaging probes targeting fibroblast activation protein α (FAP), which is overexpressed in a variety of cancer-associated fibroblasts, have become available and might constitute a feasible alternative to FDG PET/CT. METHODS: Ten consecutive, treatment-naïve patients (8 males, 2 females; mean age, 62 ± 9 years) with biopsy-proven OSCC underwent both whole-body [(18)F]FDG and [(68)Ga]FAPI-04 (FAP-directed) PET/CT for primary staging prior to tumor resection and cervical lymph node dissection. Detection of the primary tumor, as well as the presence and number of lymph node and distant metastases was analysed. Intensity of tracer accumulation was assessed by means of maximum (SUV(max)) and peak (SUV(peak)) standardized uptake values. Histological work-up including immunohistochemical staining for FAP served as standard of reference. RESULTS: [(18)F]FDG and FAP-directed PET/CT detected all primary tumors with a SUV(max) of 25.5 ± 13.2 (FDG) and 20.5 ± 6.4 (FAP-directed) and a SUV(peak) of 16.1 ± 10.3 ([(18)F]FDG) and 13.8 ± 3.9 (FAP-directed), respectively. Regarding cervical lymph node metastases, FAP-directed PET/CT demonstrated comparable sensitivity (81.3% vs. 87.5%; P = 0.32) and specificity (93.3% vs. 81.3%; P = 0.16) to [(18)F]FDG PET/CT. FAP expression on the cell surface of cancer-associated fibroblasts in both primary lesions as well as lymph nodes metastases was confirmed in all samples. CONCLUSION: FAP-directed PET/CT in OSCC seems feasible. Future research to investigate its potential to improve patient staging is highly warranted. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-021-05422-z. |
format | Online Article Text |
id | pubmed-8484183 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-84841832021-10-08 Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity – initial experience and comparison to [(18)F]FDG PET/CT and MRI Linz, Christian Brands, Roman C. Kertels, Olivia Dierks, Alexander Brumberg, Joachim Gerhard-Hartmann, Elena Hartmann, Stefan Schirbel, Andreas Serfling, Sebastian Zhi, Yingjun Buck, Andreas K. Kübler, Alexander Hohm, Julian Lapa, Constantin Kircher, Malte Eur J Nucl Med Mol Imaging Original Article PURPOSE: While [(18)F]-fluorodeoxyglucose ([(18)F]FDG) is the standard for positron emission tomography/computed tomography (PET/CT) imaging of oral squamous cell carcinoma (OSCC), diagnostic specificity is hampered by uptake in inflammatory cells such as neutrophils or macrophages. Recently, molecular imaging probes targeting fibroblast activation protein α (FAP), which is overexpressed in a variety of cancer-associated fibroblasts, have become available and might constitute a feasible alternative to FDG PET/CT. METHODS: Ten consecutive, treatment-naïve patients (8 males, 2 females; mean age, 62 ± 9 years) with biopsy-proven OSCC underwent both whole-body [(18)F]FDG and [(68)Ga]FAPI-04 (FAP-directed) PET/CT for primary staging prior to tumor resection and cervical lymph node dissection. Detection of the primary tumor, as well as the presence and number of lymph node and distant metastases was analysed. Intensity of tracer accumulation was assessed by means of maximum (SUV(max)) and peak (SUV(peak)) standardized uptake values. Histological work-up including immunohistochemical staining for FAP served as standard of reference. RESULTS: [(18)F]FDG and FAP-directed PET/CT detected all primary tumors with a SUV(max) of 25.5 ± 13.2 (FDG) and 20.5 ± 6.4 (FAP-directed) and a SUV(peak) of 16.1 ± 10.3 ([(18)F]FDG) and 13.8 ± 3.9 (FAP-directed), respectively. Regarding cervical lymph node metastases, FAP-directed PET/CT demonstrated comparable sensitivity (81.3% vs. 87.5%; P = 0.32) and specificity (93.3% vs. 81.3%; P = 0.16) to [(18)F]FDG PET/CT. FAP expression on the cell surface of cancer-associated fibroblasts in both primary lesions as well as lymph nodes metastases was confirmed in all samples. CONCLUSION: FAP-directed PET/CT in OSCC seems feasible. Future research to investigate its potential to improve patient staging is highly warranted. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-021-05422-z. Springer Berlin Heidelberg 2021-05-29 2021 /pmc/articles/PMC8484183/ /pubmed/34050405 http://dx.doi.org/10.1007/s00259-021-05422-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Linz, Christian Brands, Roman C. Kertels, Olivia Dierks, Alexander Brumberg, Joachim Gerhard-Hartmann, Elena Hartmann, Stefan Schirbel, Andreas Serfling, Sebastian Zhi, Yingjun Buck, Andreas K. Kübler, Alexander Hohm, Julian Lapa, Constantin Kircher, Malte Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity – initial experience and comparison to [(18)F]FDG PET/CT and MRI |
title | Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity – initial experience and comparison to [(18)F]FDG PET/CT and MRI |
title_full | Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity – initial experience and comparison to [(18)F]FDG PET/CT and MRI |
title_fullStr | Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity – initial experience and comparison to [(18)F]FDG PET/CT and MRI |
title_full_unstemmed | Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity – initial experience and comparison to [(18)F]FDG PET/CT and MRI |
title_short | Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity – initial experience and comparison to [(18)F]FDG PET/CT and MRI |
title_sort | targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity – initial experience and comparison to [(18)f]fdg pet/ct and mri |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484183/ https://www.ncbi.nlm.nih.gov/pubmed/34050405 http://dx.doi.org/10.1007/s00259-021-05422-z |
work_keys_str_mv | AT linzchristian targetingfibroblastactivationproteininnewlydiagnosedsquamouscellcarcinomaoftheoralcavityinitialexperienceandcomparisonto18ffdgpetctandmri AT brandsromanc targetingfibroblastactivationproteininnewlydiagnosedsquamouscellcarcinomaoftheoralcavityinitialexperienceandcomparisonto18ffdgpetctandmri AT kertelsolivia targetingfibroblastactivationproteininnewlydiagnosedsquamouscellcarcinomaoftheoralcavityinitialexperienceandcomparisonto18ffdgpetctandmri AT dierksalexander targetingfibroblastactivationproteininnewlydiagnosedsquamouscellcarcinomaoftheoralcavityinitialexperienceandcomparisonto18ffdgpetctandmri AT brumbergjoachim targetingfibroblastactivationproteininnewlydiagnosedsquamouscellcarcinomaoftheoralcavityinitialexperienceandcomparisonto18ffdgpetctandmri AT gerhardhartmannelena targetingfibroblastactivationproteininnewlydiagnosedsquamouscellcarcinomaoftheoralcavityinitialexperienceandcomparisonto18ffdgpetctandmri AT hartmannstefan targetingfibroblastactivationproteininnewlydiagnosedsquamouscellcarcinomaoftheoralcavityinitialexperienceandcomparisonto18ffdgpetctandmri AT schirbelandreas targetingfibroblastactivationproteininnewlydiagnosedsquamouscellcarcinomaoftheoralcavityinitialexperienceandcomparisonto18ffdgpetctandmri AT serflingsebastian targetingfibroblastactivationproteininnewlydiagnosedsquamouscellcarcinomaoftheoralcavityinitialexperienceandcomparisonto18ffdgpetctandmri AT zhiyingjun targetingfibroblastactivationproteininnewlydiagnosedsquamouscellcarcinomaoftheoralcavityinitialexperienceandcomparisonto18ffdgpetctandmri AT buckandreask targetingfibroblastactivationproteininnewlydiagnosedsquamouscellcarcinomaoftheoralcavityinitialexperienceandcomparisonto18ffdgpetctandmri AT kubleralexander targetingfibroblastactivationproteininnewlydiagnosedsquamouscellcarcinomaoftheoralcavityinitialexperienceandcomparisonto18ffdgpetctandmri AT hohmjulian targetingfibroblastactivationproteininnewlydiagnosedsquamouscellcarcinomaoftheoralcavityinitialexperienceandcomparisonto18ffdgpetctandmri AT lapaconstantin targetingfibroblastactivationproteininnewlydiagnosedsquamouscellcarcinomaoftheoralcavityinitialexperienceandcomparisonto18ffdgpetctandmri AT kirchermalte targetingfibroblastactivationproteininnewlydiagnosedsquamouscellcarcinomaoftheoralcavityinitialexperienceandcomparisonto18ffdgpetctandmri |